Neurologia medico-chirurgica
Original Articles
Low Peripheral Lymphocyte Count Before Focal Radiotherapy Plus Concomitant Temozolomide Predicts Severe Lymphopenia During Malignant Glioma Treatment
Eiichi ISHIKAWATetsuya YAMAMOTONoriaki SAKAMOTOKei NAKAIHiroyoshi AKUTSUKoji TSUBOIShingo TAKANOAkira MATSUMURA
Author information
JOURNALS FREE ACCESS

Volume 50 (2010) Issue 8 Pages 638-644

Details
Download PDF (261K) Contact us
Abstract

Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia. The frequency of severe lymphopenia and its predictors were analyzed by assessing adverse effects including decrease in white blood cell counts, lymphocyte counts, and neutrocyte counts according to the Common Toxicity Criteria version 3.0 (CTC) in 28 consecutive patients with pathologically verified malignant gliomas treated with radiotherapy/TMZ. Eighty-two percent of the patients suffered one or more adverse effects; lymphopenia (68%) was the most frequent adverse effect, with 32% of patients suffering CTC grade 4 lymphopenia. CTC grade 4 lymphopenia was associated with the incidence of other CTC grade 3 or 4 adverse effects and discontinuance of TMZ. Minimal lymphocyte counts during radiotherapy/TMZ and lymphocyte counts before radiotherapy/TMZ showed close linear correlation by linear regression analysis (p < 0.0001, R2 = 0.569), and the most important predictor for CTC grade 4 lymphopenia was lymphocyte count before radiotherapy/TMZ less than 1200/μl by multivariate analysis (p < 0.0321, Exp = 13.2). Lymphocyte counts before radiotherapy/TMZ of less than 1200/μl predict severe lymphopenia during radiotherapy/TMZ.

Information related to the author
Previous article Next article

Recently visited articles
feedback
Top